EP1169306A1 - Dibenzoazulenderivate zur behandlung von thrombose, osteoporose, arteriosklerose - Google Patents

Dibenzoazulenderivate zur behandlung von thrombose, osteoporose, arteriosklerose

Info

Publication number
EP1169306A1
EP1169306A1 EP00917037A EP00917037A EP1169306A1 EP 1169306 A1 EP1169306 A1 EP 1169306A1 EP 00917037 A EP00917037 A EP 00917037A EP 00917037 A EP00917037 A EP 00917037A EP 1169306 A1 EP1169306 A1 EP 1169306A1
Authority
EP
European Patent Office
Prior art keywords
formula
compounds
solvates
ylamino
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00917037A
Other languages
German (de)
English (en)
French (fr)
Inventor
Wolfgang Stähle
Rudolf Gottschlich
Simon Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1169306A1 publication Critical patent/EP1169306A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Definitions

  • the invention relates to compounds of the formula
  • R H, shark, N0 2 , NHR 4 , NA " 2 , OR 4 , S0 3 R 4 , S0 2 R 4 or SR 4 ,
  • R 5 is a mono- or dinuclear heterocycle with 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or triple by shark,
  • R 6 shark N0 2 , NHA ⁇ NA M 2 , OA ', phenoxy, CO-A', SOsA ', CN, NHCOA',
  • Ar unsubstituted or mono-, di- or trisubstituted by alkyl having 1-6 C atoms and / or R 6 mono- or dinuclear aromatic ring system with 0, 1, 2, 3 or 4 N-, O- and / or S - atoms,
  • Aralk unsubstituted or mono-, di- or trisubstituted by R 6- substituted aralkylene with 7-14 C atoms and in which one, two or three methylene groups can be replaced by N, O and / or S,
  • n each independently of one another 0, 1, 2, 3 or 4
  • the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments.
  • the GPIIa / IIIb antagonists can be regarded as effective metastasis inhibitors.
  • compounds of the formula I In addition to the binding of fibrinogen, fibronectin and von Willebrand factor to the fibrinogen receptor of the platelets, compounds of the formula I also inhibit the binding of further adhesive proteins, such as vitonectin, collagen and laminin, to the corresponding receptors on the surface of various cell types. In particular, they prevent that
  • Formation of platelet thrombi and can therefore be used to treat thrombosis, apoplexy, heart attack, inflammation and arteriosclerosis.
  • the properties of the compounds can also be demonstrated by methods which are described in EP-A1-0 462 960.
  • the inhibition of fibrinogen binding to the fibrinogen receptor can be demonstrated by the method specified in EP-A1-0 381 033.
  • the antiplatelet effect can be demonstrated in vitro by the method of Born (Nature 4832, 927-929, 1962).
  • the invention accordingly relates to the compounds of formula I according to claim 1 and their physiologically acceptable salts and Solvate as GPIIb / llla antagonists to fight thrombosis, heart attack, coronary heart disease and arteriosclerosis.
  • the invention further relates to the compounds of formula I according to claim 1 and their physiologically acceptable salts and
  • the invention relates in particular to compounds of the formula I according to claim 1 and their harmless salts and solvates, for the manufacture of a medicament for combating pathologically angiogenic diseases, tumors, osteoporosis, inflammation and
  • the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, for prophylaxis and / or
  • thrombosis myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, tumor diseases, osteolytic diseases such as osteoporosis, pathologically angiogenic diseases such as B. inflammation, ophthalmological diseases, diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis, rheumatoid arthritis, osteoarthritis, rubeotic glaucoma, ulcerative colitis, Crohn's disease, atherosclerosis, psoriasis, restenosis after angioplasty, infection, viral infection, viral infection in acute kidney failure and in wound healing to support the healing processes.
  • osteolytic diseases such as osteoporosis
  • pathologically angiogenic diseases such as B. inflammation, ophthalmological diseases, diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis, rheumatoid arthritis, osteoarthritis, rubeotic glaucoma, ulcer
  • the compounds of formula I can be used as antimicrobial substances in operations where biomaterials, implants, catheters or pacemakers are used. They have an antiseptic effect.
  • the effectiveness of the antimicrobial activity can be demonstrated by the method described by P.Valentin-Weigund et al., In Infection and Immunity, 2851-2855 (1988).
  • the invention further relates to a process for the preparation of compounds of the formula I according to claim 1 and their salts and solvates, characterized in that a) liberating a compound of the formula I from one of its functional derivatives by treatment with a solvolysing or hydrogenolysing agent,
  • the compounds of formula I have at least one chiral center and can therefore occur in several stereoisomeric forms. All of these forms (e.g. D and L forms) and their mixtures (e.g. the DL forms) are included in Formula I. So-called prodrug derivatives are also included in the compounds according to the invention, ie with z. B. alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly cleaved in the organism to the active compounds of the invention. Solvates of the compounds are also included in the compounds according to the invention. These include addition compounds with, for example, water (hydrates) or alcohols such as methanol or ethanol.
  • Trt trityl (triphenylmethyl) Z or CBZ benzyloxycarbonyl.
  • formula I comprises those compounds of the formulas I 'and I "which have a single or a double bond between C-1 and C-11a.
  • Alkyl preferably means methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.
  • -Butyl or tert-butyl also for pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2- , 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl- 1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2-, 1, 2,2-trimethylpropyl, heptyl, octyl, nonyl or decyl, and for example trifluoromethyl or pentafluoroethyl.
  • a ' is preferably H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl.
  • A preferably denotes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl.
  • Cycioalkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl,
  • Alkylene preferably means methylene, ethylene, propylene, butylene,
  • Pentylene also hexylene, heptylene, ocytylene, nonylene or decylene.
  • Aralk is aralkylene and preferably means alkylenephenyl and is e.g. preferably benzyl or phenethyl.
  • CO-A ' is alkanoyl or cycloalkanoyl and preferably means formyl, acetyl, propionyl, butyryl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, pentadecanoyl, pentadecanoyl, pentadecanoyl, pentadecanoyl, pentadecanoyl, pentadecanoyl and preferably means formyl, acetyl, propionyl, butyryl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecan
  • Preferred substituents R 6 for alkyl, Ar, cycioalkyl and aralk are preferably, for example, shark, NO 2 , NH 2 , NHA ", such as methylamino, NA" 2 , such as dimethylamino, methoxy, phenoxy, acyl such as formyl or acetyl, CN , NHCOA ', such as acetamido, COOA', such as COOH or methoxycarbonyl, CONA ' 2 or S0 2 A', in particular, for example, F, Cl, hydroxy, Methoxy, ethoxy, amino, dimethylamino, methylthio, methylsulfinyl, methylsulfonyl or phenylsulfonyl.
  • alkyl, alkylene and cycioalkyl radicals one, two or three methylene groups can each be replaced by N, O and / or S.
  • Ar-CO is aroyl and preferably means benzoyl or naphthoyl.
  • Ar is unsubstituted, preferably - as indicated - monosubstituted phenyl, in particular preferably phenyl, o-, m- or p-tolyl, o-, m- or p-
  • Ar furthermore preferably denotes 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5 -Pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 1, 2,3-triazol-1-, -4- or -5-yl, 1 , 2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl, 1, 2,4-oxadiazol-3 - or - 5-yl, 1, 3,4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3- or -5-yl, 1, 2,3-
  • R 5 is a mono- or dinuclear heterocycle, preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 1, 2,3-triazo -, -4- or -5-yl, 1, 2,4-triazoM -, -3- or 5-yl, 1 - or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl, 1, 2,4-oxadiazol-3- or -5-yl, 1 , 3,4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3- or -5-yl
  • the heterocyclic radicals can also be partially or completely hydrogenated.
  • R 5 can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-
  • R 5 very particularly preferably denotes 1 H-imidazol-2-yl, 4,5-dihydro-1 H-imidazol-2-yl, 5-oxo-4, 5-dihydro-1 H-imidazol-2-yl, thiazole -2-yl, 1 H-benzimidazol-2-yl, 2H-pyrazol-2-yl, 1 H-tetrazol-5-yl, 2-imino-imidazolidin-4-one, 5-yl, 1-alkyl -1,5-dihydro-imidazol-4-one-2-yl, pyridin-2-yl, pyrimidin-2-yl or 1,4,5,6-tetrahydro-pyrimidin-2-yl.
  • R 1 means in particular, for example, carboxy, methoxycarbonyl, ethoxycarbonyl, CONH 2) CONHMe, CONHEt, CONMe 2 or CONEt 2 .
  • R 1 very particularly preferably denotes carboxy or ethoxycarbonyl.
  • R 2 preferably denotes, for example, H, shark, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, isobutylsulfonyl, 2,2-dimethylpropylsulfonyl,
  • R 2 very particularly preferably denotes H.
  • the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
  • Some preferred groups of compounds can be expressed by the following sub-formulas Ia to Ih, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
  • R 2 denotes H; in Ib) R 2 H and
  • R 1 is COOH or COOA; in Ic) R 2 H,
  • R 2 represents H; in lf) R 2 H,
  • R 1 is COOH or COOA and m is 0 or 1; in ig) R 2 H,
  • A is methyl, ethyl, propyl, isopropyl, butyl or tert-butyl and m is 0 or 1; in Ih) R 2 H,
  • the compounds of the formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are described, namely under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail. If desired, the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
  • Compounds of the formula I can preferably be obtained by liberating compounds of the formula I from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
  • Preferred starting materials for solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and / or hydroxyl groups contain corresponding protected amino and / or hydroxyl groups, preferably those which instead of an H atom, which is connected to an N atom carry an amino protective group, in particular those which carry an R'-N group instead of an HN group, in which R 'represents an amino protective group, and / or those which instead of the H- Atoms of a hydroxyl group carry a hydroxyl protective group, for example those which correspond to the formula I, but instead of a group -COOH carry a group -COOR "in which R" denotes a hydroxyl protective group.
  • amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other locations in the molecule. Unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups are particularly typical of such groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their type and size is otherwise not critical; however, preference is given to those having 1-20, in particular 1-8, carbon atoms.
  • acyl group is related with the present procedure in the broadest sense.
  • acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
  • alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups are alkanoyl such as
  • Preferred amino protective groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
  • the amino protective group is split off, depending on the protective group used, e.g. B. with strong acids, suitably with TFA or perchloric acid, but also with other strong inorganic acids such as
  • Hydrochloric acid or sulfuric acid strong organic carboxylic acids such as trichloroacetic acid or sulfonic acids such as benzene or p-toluenesulfonic acid.
  • carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are also suitable.
  • TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in a ratio of 9: 1.
  • the reaction temperatures for the cleavage are advantageously between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).
  • the groups BOC, OBut and Mtr can e.g. B. preferably with TFA in dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 °, the FMOC group with an about 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 °.
  • Hydrogenolytically removable protective groups e.g. CBZ or benzyl
  • a catalyst z. B. a noble metal catalyst such as palladium, advantageously on a support such as coal.
  • Suitable solvents are the above, especially z. B. alcohols such as
  • Methanol or ethanol or amides such as DMF Methanol or ethanol or amides such as DMF.
  • the hydrogenolysis is generally carried out at temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° and 1-10 bar.
  • Hydrogenolysis of the CBZ group succeeds e.g. B. good at 5 to 10% Pd / C in methanol or with ammonium formate (instead of
  • Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF);
  • a carboxylic acid ester can be converted into a carboxylic acid.
  • amidinizing agent is 1-amidino-3,5-dimethylpyrazole (DPFN), which is used in particular in the form of its nitrate.
  • DPFN 1-amidino-3,5-dimethylpyrazole
  • the addition is preferably carried out in several stages by, in a manner known per se, a) converting the nitrile with H 2 S into a thioamide, which is converted into the corresponding S-alkylimidothioester using an alkylating agent, for example CH 3 I, which in turn, reacts with NH 3 to form the amidine, b) converting the nitrile with an alcohol, for example ethanol in the presence of HCl, into the corresponding imidoester and treating it with ammonia, or c) reacting the nitrile with lithium bis (trimethylsilyl) amide and the product then hydrolyzed.
  • an alkylating agent for example CH 3 I
  • free amino groups can be acylated in the usual way with an acid chloride or anhydride or alkylated with an unsubstituted or substituted alkyl halide, advantageously in an inert solvent such as dichloromethane or THF and / or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and + 30 °.
  • a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
  • acids that provide physiologically acceptable salts are suitable for this implementation.
  • inorganic acids can be used, for example sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or poly-based carbon, sulfonic or Sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid,
  • Ascorbic acid nicotinic acid, isonicotinic acid, methane or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene-mono- and disulfonic acids, lauryl-sulfuric acid.
  • Salts with physiologically unacceptable acids, e.g. Picrates can be used for the isolation and / or purification of the compounds of the formula I.
  • an acid of the formula I can be converted into one of its physiologically acceptable metal or ammonium salts by reaction with a base.
  • Suitable salts are, in particular, the sodium, potassium, magnesium, calcium and ammonium salts, and also substituted ammonium salts, e.g. B. the dimethyl, diethyl or diisopropyl ammonium salts, monoethanol, diethanol or diisopropylammonium salts, cyclohexyl, dicyclohexylammonium salts, dibenzylethylenediammonium salts, z. B. salts with arginine or
  • the compounds of the formula I contain one or more chiral centers and can therefore be present in racemic or in optically active form. Racemates obtained can be separated mechanically or chemically into the enantiomers by methods known per se. Preferably diastereomers are formed from the racemic mixture by reaction with an optically active release agent.
  • Suitable release agents are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphor sulfonic acids such as ⁇ -camphor sulfonic acid.
  • Enantiomer separation using a column filled with an optically active separating agent is also advantageous; a mixture of hexane / isopropanol / acetonitrile, for example in a volume ratio of 82: 15: 3, is suitable as the mobile phase.
  • an optically active separating agent for example dinitrobenzoylphenylglycine
  • optically active compounds of the formula I by the methods described above by using starting materials which are already optically active.
  • the invention further relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
  • the invention further relates to pharmaceutical preparations containing at least one compound of the formula I and / or one of its physiologically acceptable salts.
  • Suitable carriers are organic or inorganic substances that are suitable for enteral (e.g. oral), parenteral, topical application or for application in the form of a
  • Inhalation sprays are suitable and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used in particular for oral use, while sup- positions, for parenteral application solutions, preferably oily or aqueous solutions, further suspensions, emulsions or implants, for topical application ointments, creams or powders.
  • parenteral application solutions preferably oily or aqueous solutions, further suspensions, emulsions or implants, for topical application ointments, creams or powders.
  • the new compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injectables.
  • the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or one or more further active ingredients, e.g. B. one or more vitamins.
  • sprays can be used which contain the active ingredient either dissolved or suspended in a propellant gas or propellant gas mixture (e.g. C0 2 or chlorofluorocarbons).
  • a propellant gas or propellant gas mixture e.g. C0 2 or chlorofluorocarbons.
  • the active ingredient is expediently used in micronized form, with one or more additional physiologically tolerable ones
  • Solvents may be present, e.g. B. ethanol. Inhalation solutions can be administered using standard inhalers.
  • the invention also relates to the use of the compounds of the formula I as therapeutic active ingredients.
  • the compounds of the formula I and their physiologically acceptable salts can be used as integrin inhibitors in combating diseases, in particular pathologically angiogenic diseases, thromboses, heart attacks, coronary heart diseases, arteriosclerosis, tumors, inflammations and infections.
  • the substances according to the invention can generally be administered in analogy to other known, commercially available integrin inhibitors, but in particular in analogy to the compounds described in US Pat. No. 4,472,305, preferably in doses between about 0.05 and 500 mg , in particular between 0.5 and 100 mg administered per dosage unit.
  • the daily dosage is preferably between about 0.01 and 2 mg / kg body weight.
  • the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the special compounds used. the age, body weight, general state of health, gender, the diet, the time and route of administration, the rate of excretion, the combination of drugs and the severity of the disease to which the therapy applies. Parenteral administration is preferred.
  • customary work-up means: if necessary, water is added, and if necessary, depending on the constitution of the end product, the pH is adjusted to between 2 and 10, extracted with ethyl acetate or dichloromethane, separated off, dries the organic phase over sodium sulfate, evaporates and purifies by chromatography on silica gel and / or by crystallization.
  • the specified Rf values were determined by thin layer chromatography using TLC films, silica gel 60 F 254 .
  • a catalytic amount of DMAP is added to a solution of 0.3 g of "AE" in 18 ml of dichloromethane and 0.14 ml of triethylamine.
  • the mixture is cooled in an ice bath, 0.063 ml of methanesulfonyl chloride are added and the mixture is subsequently stirred at room temperature for 14 hours.
  • the mixture is filtered through silica gel 60 (petroleum ether / ethyl acetate 5: 1). After the solvents have been removed, the residue is dissolved in 50 ml of toluene, 0.179 g of DBU are added and the mixture is stirred at 80 ° for 16 hours.
  • Example A Injection glasses
  • a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
  • a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
  • a solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH 2 P0 4 • 2 H 2 0, 28.48 g Na 2 HP0 4 • 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
  • Example D ointment
  • 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
  • Example F coated tablets
  • Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
  • Example G capsules
  • each capsule contains 20 mg of the active ingredient.
  • a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00917037A 1999-04-14 2000-04-01 Dibenzoazulenderivate zur behandlung von thrombose, osteoporose, arteriosklerose Withdrawn EP1169306A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19916837A DE19916837A1 (de) 1999-04-14 1999-04-14 Dibenzoazulenderivate
DE19916837 1999-04-14
PCT/EP2000/002925 WO2000063178A1 (de) 1999-04-14 2000-04-01 Dibenzoazulenderivate zur behandlung von thrombose, osteoporose, arteriosklerose

Publications (1)

Publication Number Publication Date
EP1169306A1 true EP1169306A1 (de) 2002-01-09

Family

ID=7904536

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00917037A Withdrawn EP1169306A1 (de) 1999-04-14 2000-04-01 Dibenzoazulenderivate zur behandlung von thrombose, osteoporose, arteriosklerose

Country Status (19)

Country Link
US (1) US6521646B1 (pt)
EP (1) EP1169306A1 (pt)
JP (1) JP2002542231A (pt)
KR (1) KR20010102570A (pt)
CN (1) CN1345312A (pt)
AR (1) AR023496A1 (pt)
AU (1) AU3817400A (pt)
BR (1) BR0009690A (pt)
CA (1) CA2367359A1 (pt)
CZ (1) CZ20013704A3 (pt)
DE (1) DE19916837A1 (pt)
HU (1) HUP0200643A3 (pt)
MX (1) MXPA01010294A (pt)
NO (1) NO20014976D0 (pt)
PL (1) PL350354A1 (pt)
RU (1) RU2001129708A (pt)
SK (1) SK14342001A3 (pt)
WO (1) WO2000063178A1 (pt)
ZA (1) ZA200109343B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4964389B2 (ja) 2000-06-30 2012-06-27 ダウ グローバル テクノロジーズ エルエルシー 多環式、縮合環化合物、金属錯体及び重合方法
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2005117954A2 (en) 2004-06-04 2005-12-15 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795709A (en) * 1968-02-07 1974-03-05 Sandoz Ag Benzobenzazulenes
DK0820426T3 (da) * 1995-03-09 2000-07-31 Ortho Pharma Corp Substituerede dibenz[a,f]azulener og fremgangsmåde til fremstilling deraf
PT910563E (pt) * 1995-06-29 2003-09-30 Smithkline Beecham Corp Antagonistas de receptores de integrina
SK282894B6 (sk) * 1996-03-20 2003-01-09 Hoechst Marion Roussel Tricyklické zlúčeniny, spôsob ich prípravy a medziprodukty tohto spôsobu, ich použitie ako liečiv a farmaceutické zmesi, ktoré ich obsahujú
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0063178A1 *

Also Published As

Publication number Publication date
ZA200109343B (en) 2003-04-30
RU2001129708A (ru) 2004-02-27
KR20010102570A (ko) 2001-11-15
NO20014976L (no) 2001-10-12
SK14342001A3 (sk) 2002-04-04
HUP0200643A3 (en) 2003-10-28
JP2002542231A (ja) 2002-12-10
WO2000063178A1 (de) 2000-10-26
CA2367359A1 (en) 2000-10-26
US6521646B1 (en) 2003-02-18
NO20014976D0 (no) 2001-10-12
PL350354A1 (en) 2002-12-02
HUP0200643A2 (hu) 2002-07-29
CZ20013704A3 (cs) 2002-02-13
CN1345312A (zh) 2002-04-17
MXPA01010294A (es) 2002-05-06
DE19916837A1 (de) 2000-10-19
BR0009690A (pt) 2002-01-08
AR023496A1 (es) 2002-09-04
AU3817400A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
EP0907637A1 (de) Phenylalanin-derivate als integrin-inhibitoren
EP0964856B1 (de) Bicyclische aromatische aminosäuren
DE19654483A1 (de) Phenylalanin-Derivate
WO1997023451A1 (de) Tyrosin-derivate als alpha-v-integrin-inhibitoren
WO2000003973A1 (de) Diacylhydrazinderivate als integrin-inhibitoren
DE10112771A1 (de) Inhibitoren des Integrins alpha¶v¶beta¶6¶
WO2000026212A1 (de) Chromenon- und chromanonderivate als integrinhemmer
DE19713000A1 (de) Adhäsionsrezeptor-Antagonisten
EP1194401B1 (de) Diacylhydrazinderivate
EP1206455A1 (de) INHIBITOREN DES INTEGRINS ALPHAvBETA3
DE10118550A1 (de) Liganden des Integrins alpha¶nu¶beta¶6¶
EP1169306A1 (de) Dibenzoazulenderivate zur behandlung von thrombose, osteoporose, arteriosklerose
EP1594853A1 (de) Verfahren zur herstellung bicyclischer aromatischer aminosäuren sowie deren zwischenprodukte
EP0948525A1 (de) Cyclopeptidderivate
WO2001014338A1 (de) NEUE INHIBITOREN DES INTEGRINS αVβ¿3?
WO2001010841A2 (de) Fluorenderivate als integrin inhibitoren
WO2002098858A1 (de) Integrinantagonisten
WO2003014088A1 (de) Biphenylthioamide als integrinrezeptorantagonisten
WO1998018764A1 (de) Dihydrobenzoanthracenone, -pyrimidinone oder dihydronaphthochinolinone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20010817;LV PAYMENT 20010817;MK;RO PAYMENT 20010817;SI PAYMENT 20010817

17Q First examination report despatched

Effective date: 20031013

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031031